There are 2789 resources available
1016P - ImmTAC redirect exhausted tumor-infiltrating T-cells: An effect enhanced by pembrolizumab against PD-L1+ tumors
Presenter: Kristina Petrovic
Session: ePoster Display
1017P - Preclinical evaluation of KD033, a human anti-PD-L1/IL-15 bispecific protein, in human PD-1/PD-L1 transgenic C57/Bl6 mice with PD-L1 positive and negative tumors
Presenter: Stella Martomo
Session: ePoster Display
1018P - Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
Presenter: Bartosz Chmielowski
Session: ePoster Display
926TiP - Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
Presenter: Grzegorz Obara
Session: ePoster Display
928TiP - Induction versus adjuvant gemcitabine/cisplatin in locally advanced non-metastatic nasopharyngeal carcinoma: A randomised phase III trial
Presenter: Shereen Masoud
Session: ePoster Display
929TiP - HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
Presenter: Amanda Psyrri
Session: ePoster Display
930TiP - innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors
Presenter: David Hong
Session: ePoster Display
931TiP - Malnutrition based on the GLIM criteria and the response to concurrent chemoradiotherapy in patients with squamous cell carcinoma of the head and neck
Presenter: Maria João de Sousa
Session: ePoster Display